Treatment of vitiligo with khellin and ultraviolet A.
Twenty-eight patients with vitiligo were treated with a new photochemotherapeutic regimen using khellin, a furanochromone, as photosensitizer, together with ultraviolet A (UVA) irradiation. Twenty-five patients received khellin orally and three patients were treated with topical khellin. Treatments were given three times weekly. As opposed to psoralens, khellin did not induce skin phototoxicity with UVA but it induced repigmentation similar to psoralens. The treatment success strongly depended on the number of treatments. More than 70% repigmentation was achieved in 41% of the patients who had received 100 to 200 treatments. This success rate is comparable to the rate obtained with psoralens. Seven patients experienced a mild elevation of liver transaminases within the early treatment phase and their treatments were discontinued. No long-term internal organ or skin toxicity was observed. The major advantage of khellin is that it does not lead to phototoxic skin erythema and thus can be considered safe for home treatment. Because of its photochemistry it may be considered less hazardous than psoralens regarding mutagenicity and carcinogenicity.
Ortel
B
B
Department of Dermatology I, University of Vienna, Austria.
Tanew
A
A
Hönigsmann
H
H
D000293:Adolescent; D000328:Adult; D002648:Child; D004890:Erythema / Q000209:etiology; D005260:Female; D006801:Humans; D007666:Khellin / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D012880:Skin Pigmentation / Q000187:drug effects; D014467:Ultraviolet Therapy; D014820:Vitiligo / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
D007666:Khellin